March 21, 2008

AstraZenca Waiting to be Found

The Stockmasters has a write up on the U.K.'s second largest drug manufacturer, AstraZenca. This company is close to its 52 week low, has 10 drugs in Phase 3 Trials and their lineup of 12 drugs rake in more than $1 billion a year in revenue. Plus, this stock pays a 5% dividend. HSBC just upgraded the stock with a $51 price target.

No comments: